Timothy Pigot - 07 Mar 2023 Form 3 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Chief Commercial Officer
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
07 Mar 2023
Net transactions value
$0
Form type
3
Filing time
08 Mar 2023, 17:01:03 UTC
Next filing
24 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AVTE Common Stock 1,960 07 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AVTE Stock Option (Right to Buy) 07 Mar 2023 Common Stock 77,000 $14.00 Direct F2
holding AVTE Stock Option (Right to Buy) 07 Mar 2023 Common Stock 30,000 $10.61 Direct F3
holding AVTE Stock Option (Right to Buy) 07 Mar 2023 Common Stock 74,000 $25.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F2 25% of this option vested and became exercisable on June 14, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3 This option shall vest in 48 substantially equal monthly installments, with the first installment vested on January 14, 2022.
F4 This option shall vest in 48 substantially equal monthly installments, with the first installment vested on March 7, 2023.